{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/menorrhagia/prescribing-information/tranexamic-acid/","result":{"pageContext":{"chapter":{"id":"c6b368dc-8409-55ee-8072-ffa3dc54a6f0","slug":"tranexamic-acid","fullItemName":"Tranexamic acid","depth":2,"htmlHeader":"<!-- begin field d593e046-e93f-4bb9-acfc-a73f009054ad --><h2>Tranexamic acid</h2><!-- end field d593e046-e93f-4bb9-acfc-a73f009054ad -->","summary":"","htmlStringContent":"<!-- begin item 3fe4326a-05de-4bd8-ac2e-a73f00905557 --><!-- end item 3fe4326a-05de-4bd8-ac2e-a73f00905557 -->","topic":{"id":"d4abfe41-b89f-5d51-8168-7ff98b4290f9","topicId":"4013d716-0ba5-4984-bfb1-8c7eca832ba8","topicName":"Menorrhagia","slug":"menorrhagia","lastRevised":"Last revised in December 2018","chapters":[{"id":"0e4b035a-9880-5848-b317-d92515f750d7","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"98c45e96-1179-53a4-9b74-a5f71fffaebd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"73a36e11-2419-5f1f-9d0a-989641466fbf","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"49315340-c2d5-5025-a18d-ab2347baae5b","slug":"changes","fullItemName":"Changes"},{"id":"a232dfd0-a500-5e6b-9ead-3c3c94f0d2cf","slug":"update","fullItemName":"Update"}]},{"id":"cdc50c06-ff06-509a-be3e-1047ea50bc07","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"e5043cba-12e2-5f47-aac7-4e74d516a7fa","slug":"goals","fullItemName":"Goals"},{"id":"b1ea37fe-6d24-5529-9f7e-c0e49ccba796","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cf03761e-6677-5ba5-ac47-f290b7cb66ec","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"24f740a2-df74-5305-b364-52d1fa68040a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"913b3856-8846-53a2-86c7-f489c766e0f4","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"45c06974-d676-5c1e-bc8f-269a8c65df4f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7d698fba-d82e-55be-bcc0-0ee11398e628","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"aa066829-e43c-5a83-b602-2680d838463a","slug":"definition","fullItemName":"Definition"},{"id":"37436c25-6db1-5e7c-b8fd-7590cd5ca25d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e5c102c5-46d5-5096-bb8b-d2ef0960e353","slug":"causes","fullItemName":"Causes"},{"id":"b7f926cd-7de3-5b25-9697-78920cccf7b7","slug":"complications","fullItemName":"Complications"}]},{"id":"305d1c2b-5b47-5eda-adc5-03782afe2229","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"fc278e0b-a1a4-54d5-b44c-ddde104596ea","slug":"assessment","fullItemName":"Assessment"},{"id":"1d41d3f0-3049-510f-982a-9d9c39c5d52f","slug":"investigations-for-the-cause-of-menorrhagia","fullItemName":"Investigations for the cause of menorrhagia"}]},{"id":"5c051ed4-4e95-59b7-8bf1-c9e426198f5f","fullItemName":"Management","slug":"management","subChapters":[{"id":"e30d2783-35fc-5470-9fb3-b8a643f83450","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"324cd8d0-2857-5c2b-bd8e-ac2d83c5b55d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c6b368dc-8409-55ee-8072-ffa3dc54a6f0","slug":"tranexamic-acid","fullItemName":"Tranexamic acid"},{"id":"13dd98d9-6054-5177-8564-df8c7ede9e5c","slug":"nonsteroidal-anti-inflammatory-drugs","fullItemName":"Nonsteroidal anti-inflammatory drugs"},{"id":"0e5ebc73-f73e-5d12-9e9a-82f8373fc507","slug":"oral-norethisterone","fullItemName":"Oral norethisterone"}]},{"id":"5964d183-6ca2-5e15-9a46-bd0c666e6146","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"443b20d0-895a-5b92-810b-17af26ab31e6","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"93531fdf-665e-5277-9d61-5b62984a866f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"949f5d38-0e7a-59b8-a641-b1096ac7f3b3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"dd5aaa9a-b897-51a6-b133-d7e4170711df","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"81610614-c77a-5340-b5b3-721aafb19cc3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"83d1c27f-0003-5757-b8a1-90f777106d61","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8fe218e8-4e7d-55af-9b5b-4f2bad344402","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"324cd8d0-2857-5c2b-bd8e-ac2d83c5b55d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"8bfabfe7-1c93-5f82-a842-38ece8374c91","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field ff9b7e0d-2b4f-445f-9173-a73f009213a1 --><h3>Dose</h3><!-- end field ff9b7e0d-2b4f-445f-9173-a73f009213a1 -->","summary":"","htmlStringContent":"<!-- begin item 81f9f6df-a367-48a1-bf0a-a73f0092131a --><!-- begin field 6161d224-84ca-4a4f-9f12-a73f009213a1 --><ul><li>Tranexamic acid is licensed for the treatment of menorrhagia.</li><li>Prescribe two 500 mg tablets three times a day, for up to 4 days. The dose may be increased to a maximum of 4 g (8 tablets) daily if required.</li><li>Advise women:<ul><li>That the tablets should only be taken once menstrual bleeding has started.</li><li>To continue using tranexamic acid for as long as they are found to be beneficial. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">NICE, 2018</a>] </p><!-- end field 6161d224-84ca-4a4f-9f12-a73f009213a1 --><!-- end item 81f9f6df-a367-48a1-bf0a-a73f0092131a -->","subChapters":[]},{"id":"c5e47132-5a95-57be-8450-173e5b876c4d","slug":"contraindications","fullItemName":"Contraindications","depth":3,"htmlHeader":"<!-- begin field 40b62c22-2c55-4674-8238-a73f0091ebe3 --><h3>Contraindications and cautions</h3><!-- end field 40b62c22-2c55-4674-8238-a73f0091ebe3 -->","summary":"","htmlStringContent":"<!-- begin item 84119292-cf68-4908-b2f6-a73f0091eca0 --><!-- begin field dbb76de0-ec8d-47fc-aaa2-a73f0091ebe3 --><ul><li>Do not prescribe tranexamic acid to women with:<ul><li>Fibrinolytic conditions following disseminated intravascular coagulation.</li><li>History of convulsions.</li><li>Severe renal impairment (risk of accumulation).</li><li>A history of (or active) thromboembolic disease (for example, DVT, or pulmonary embolism).</li></ul></li><li>Prescribe tranexamic acid with caution to women: <ul><li>With irregular menstrual bleeding.</li><li>Haematuria.</li><li>Taking oral contraceptives.</li><li>Taking warfarin or other anticoagulants.  </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">BNF 73, 2017</a>] </p><!-- end field dbb76de0-ec8d-47fc-aaa2-a73f0091ebe3 --><!-- end item 84119292-cf68-4908-b2f6-a73f0091eca0 -->","subChapters":[]},{"id":"17d06bf4-f2e3-5f0e-bb3f-e90647b0a150","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 5efac974-5698-468c-b62d-a73f009222af --><h3>Adverse effects</h3><!-- end field 5efac974-5698-468c-b62d-a73f009222af -->","summary":"","htmlStringContent":"<!-- begin item c72d272a-8635-4dbf-9336-a73f00922386 --><!-- begin field b6783139-9d0f-4ce8-af2e-a73f009222af --><ul><li>Possible adverse effects include: <ul><li>Gastrointestinal effects, for example, nausea, vomiting, diarrhoea (common). </li><li>Allergic dermatitis (uncommon).</li><li>Visual disturbances (rare).</li><li>Thromboembolic events (rare).</li><li>Convulsions (frequency unknown).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">BNF 73, 2017</a>]</p><!-- end field b6783139-9d0f-4ce8-af2e-a73f009222af --><!-- end item c72d272a-8635-4dbf-9336-a73f00922386 -->","subChapters":[]},{"id":"b8bff9ed-83a8-57bf-bedb-25d892cec96a","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field d94191df-b255-4b68-87fc-a7a200704e70 --><h3>Drug interactions</h3><!-- end field d94191df-b255-4b68-87fc-a7a200704e70 -->","summary":"","htmlStringContent":"<!-- begin item 310cebb6-01f0-49fb-95d3-a7a200704c3f --><!-- begin field 3bae2005-7d75-490c-8d51-a7a200704e70 --><ul><li>Drug interactions may occur with:<ul><li>Anticoagulants — increased risk of thrombosis.</li><li>Oral contraceptives — increased risk of thrombosis. </li><li>Chlorpromazine — increased risk of bleeding.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">ABPI, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">Micromedex, 2016</a>]</p><!-- end field 3bae2005-7d75-490c-8d51-a7a200704e70 --><!-- end item 310cebb6-01f0-49fb-95d3-a7a200704c3f -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}